IL1B and neoplasm: CAR-M recruited CD3 T cells and reduced PD-L1+ cells at the tumor site—confirming that the engineered Mφ was not the only driver of the anti-tumor response—and increased serum levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, demonstrating a systemic immune response [52,56].